Charles Schwab Investment Management Inc. Sells 8,719 Shares of Glaukos Corporation $GKOS

Key Points

• Charles Schwab Investment Management Inc. reduced its stake in Glaukos Corporation by 1.3%, selling 8,719 shares, and now holds approximately 641,978 shares valued at $63.18 million.
• Analysts have mixed ratings on Glaukos, with one sell rating, two hold ratings, ten buy ratings, and a consensus target price of $127.42.
• Glaukos reported a 29.7% increase in quarterly revenue year-over-year, totaling $124.12 million, but still posted a loss of ($0.24) earnings per share, slightly beating analyst expectations.

Charles Schwab Investment Management Inc. reduced its holdings in Glaukos Corporation (NYSE:GKOS - Free Report) by 1.3% during the 1st quarter, according to the company in its most recent disclosure with the SEC. The fund owned 641,978 shares of the medical instruments supplier's stock after selling 8,719 shares during the quarter. Charles Schwab Investment Management Inc. owned about 1.12% of Glaukos worth $63,183,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Bessemer Group Inc. grew its position in shares of Glaukos by 133.9% in the first quarter. Bessemer Group Inc. now owns 276 shares of the medical instruments supplier's stock valued at $27,000 after purchasing an additional 158 shares during the last quarter. Whipplewood Advisors LLC grew its position in shares of Glaukos by 3,957.1% in the first quarter. Whipplewood Advisors LLC now owns 284 shares of the medical instruments supplier's stock valued at $28,000 after purchasing an additional 277 shares during the last quarter. First Horizon Advisors Inc. grew its position in shares of Glaukos by 72.9% in the first quarter. First Horizon Advisors Inc. now owns 377 shares of the medical instruments supplier's stock valued at $37,000 after purchasing an additional 159 shares during the last quarter. Versant Capital Management Inc grew its position in shares of Glaukos by 583.9% in the first quarter. Versant Capital Management Inc now owns 383 shares of the medical instruments supplier's stock valued at $38,000 after purchasing an additional 327 shares during the last quarter. Finally, CoreCap Advisors LLC grew its position in shares of Glaukos by 36.4% in the fourth quarter. CoreCap Advisors LLC now owns 750 shares of the medical instruments supplier's stock valued at $112,000 after purchasing an additional 200 shares during the last quarter. 99.04% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on the company. Morgan Stanley decreased their target price on Glaukos from $110.00 to $72.00 and set an "underweight" rating on the stock in a research report on Tuesday, May 6th. Stifel Nicolaus decreased their target price on Glaukos from $140.00 to $115.00 and set a "buy" rating on the stock in a research report on Thursday, May 1st. UBS Group lifted their target price on Glaukos from $125.00 to $134.00 and gave the stock a "buy" rating in a research report on Thursday, July 31st. Truist Financial reissued a "buy" rating and set a $135.00 target price (down from $140.00) on shares of Glaukos in a research report on Thursday, May 1st. Finally, BTIG Research reissued a "buy" rating on shares of Glaukos in a research report on Monday, July 14th. One analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat, Glaukos has a consensus rating of "Moderate Buy" and a consensus price target of $127.42.

Glaukos Price Performance

GKOS traded down $0.3840 during midday trading on Tuesday, reaching $89.1360. 70,197 shares of the company's stock were exchanged, compared to its average volume of 954,806. The firm has a market capitalization of $5.11 billion, a price-to-earnings ratio of -54.03 and a beta of 0.78. The company has a quick ratio of 4.69, a current ratio of 5.51 and a debt-to-equity ratio of 0.09. Glaukos Corporation has a one year low of $77.10 and a one year high of $163.71. The business has a 50-day simple moving average of $96.74 and a two-hundred day simple moving average of $102.50.

Glaukos (NYSE:GKOS - Get Free Report) last announced its quarterly earnings results on Wednesday, July 30th. The medical instruments supplier reported ($0.24) EPS for the quarter, topping analysts' consensus estimates of ($0.26) by $0.02. The firm had revenue of $124.12 million during the quarter, compared to analysts' expectations of $115.49 million. Glaukos had a negative net margin of 21.43% and a negative return on equity of 8.59%. The company's revenue for the quarter was up 29.7% compared to the same quarter last year. During the same quarter last year, the company earned ($0.52) earnings per share. Glaukos has set its FY 2025 guidance at EPS. As a group, research analysts predict that Glaukos Corporation will post -1.08 EPS for the current year.

Glaukos Company Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.